It has been predicted that the prevalence rate of inflammatory bowel disease will double and will be affecting up to 0.32% of the total population in the coming years, starting from 0.18% in 2016. Though inflammatory bowel disease is said to be a disease of the emerged nations, still owing to the development and urbanization of poorer nations, it is expected that the occurrence rate of this disease will rise even in developing nations. The rising prevalence of this disease will bring in new opportunities for the manufacturers in the market to come up with new therapies for the treatment of the symptoms of patients in a more effective manner as compared to those currently available. The market has been categorized into two main applications, namely diagnostic and therapeutic.
This report comprises an extensive analysis of the global inflammatory bowel disease market and encapsulates the drivers and restraints impacting the development of this market. The prevalent trends in the market and the investment opportunities have also been presented through this study. These trends will help the upcoming companies to plan their investment strategies accordingly in order to experience a better penetration in the market.
The report also employs exemplified SWOT evaluation and Porter’s five forces model for making the readers acquainted with the competition prevalent in the global inflammatory bowel disease market. The vendor analysis section of the report throws light on the key vendors coupled with the portfolios of their competitive performances. The strengths and weakness of the key players operating in the market for inflammatory bowel disease have also been encapsulated under the competitive landscape section of the report. Furthermore, the late-stage pipeline molecules introduced in order to treat this disease have also been discussed under this study.
The global inflammatory bowel disease market is fuelled by the growing utilization of biological therapies such as monoclonal antibodies. Biologics hold a significant position in the market for the treatment of patients suffering from inflammatory bowel disease. Hence, biologics are poised to emerge as the most preferred treatment option in this market, thus positively impacting the overall growth of this market. In addition, the growing occurrence rate of inflammatory bowel disease will also provide impetus to the growth of the overall market. On the other hand, the soaring cost of drugs utilized may work against the development of this market.
In terms of geography, the Europe and North America global inflammatory bowel disease markets hold a significant position. In addition, the developing nations of Japan, Russia, and India will also hold a significant share in the inflammatory bowel disease market. On the other hand, the regions of Latin America and the Middle East will also exhibit strong development in this market. The reasons for the superiority of these two regions include the shifting lifestyles of individuals and the soaring industrialization in these regions, hence making them more prone to diseases.
The prominent players operating in the global inflammatory bowel disease market are Abbott Laboratories, Bristol-Myers Squibb Company, Amgen, Inc., Alcon, Inc., Johnson & Johnson, Sequella, Inc., Baxter International, Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Eisai Co. Ltd., Osiris Therapeutics, Inc., Cephalon, Inc., Pfizer, Inc., Celltrion, Inc., Soligenix, Inc., Pluristem Therapeutics, Inc., and Ore Pharmaceuticals, Inc., among others.